Institute for Clinical & Economic Review to Assess Treatments for High Cholesterol
June 13, 2020
June 13, 2020
BOSTON, Massachusetts, June 13 -- The Institute for Clinical and Economic Review issued the following announcement:
The Institute for Clinical and Economic Review (ICER) announced that it will assess the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (Nexletol(TM), Esperion Therapeutics, Inc.) for treatment of high cholesterol in the setting of heterozygous familial hypercholesterolemia or secondary prevention of ASCVD. Inclisiran is current . . .
The Institute for Clinical and Economic Review (ICER) announced that it will assess the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (Nexletol(TM), Esperion Therapeutics, Inc.) for treatment of high cholesterol in the setting of heterozygous familial hypercholesterolemia or secondary prevention of ASCVD. Inclisiran is current . . .